Division of Hematology-Oncology, Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA.
Hum Gene Ther. 2011 Mar;22(3):257-62. doi: 10.1089/hum.2011.1104. Epub 2011 Feb 2.
Mesenchymal stromal cells (MSCs) have been shown to mediate immune responses in vitro and in vivo. These observations have led to clinical trials of MSC administration to ameliorate acute graft-versus-host disease (GVHD), the most serious complication arising after allogeneic hematopoietic cell transplantation. Clinical data suggest a benefit in approximately two-thirds of patients with steroid-resistant acute GVHD. Preliminary studies have been reported on the use of MSCs to treat de novo acute GVHD, for prophylaxis of the condition, and more recently, in the management of chronic GVHD. Although preclinical data inferred a possible role of MSCs in affecting GVHD mechanisms, more robust animal models became available only after numerous clinical trials with these cells had been undertaken. Further clinical trials, the development of more appropriate animal models and an effective means of tracking and imaging the introduced cells in real time in patients, are required to better define their role in this important area of medicine.
间充质基质细胞（MSCs）已被证明可在体外和体内调节免疫反应。这些观察结果导致了 MSC 给药以改善急性移植物抗宿主病（GVHD）的临床试验，GVHD 是异基因造血细胞移植后最严重的并发症。临床数据表明，大约三分之二的类固醇耐药性急性 GVHD 患者从中受益。已经有关于使用 MSC 治疗新发急性 GVHD、预防该病以及最近治疗慢性 GVHD 的初步研究报告。尽管临床前数据推断 MSC 可能在影响 GVHD 机制方面发挥作用，但只有在对这些细胞进行了多次临床试验之后，才出现了更强大的动物模型。需要进一步的临床试验、开发更合适的动物模型以及实时跟踪和成像引入患者的细胞的有效手段，以更好地确定它们在这一重要医学领域中的作用。
